Molecular Neurobiology,
Journal Year:
2022,
Volume and Issue:
60(3), P. 1476 - 1485
Published: Dec. 7, 2022
Abstract
Examination
of
post-mortem
brain
tissues
has
previously
revealed
a
strong
association
between
Parkinson’s
disease
(PD)
pathophysiology
and
endoplasmic
reticulum
(ER)
stress.
Evidence
in
the
literature
regarding
circulation
ER
stress-regulated
factors
released
from
neurons
provides
rationale
for
investigating
stress
biomarkers
blood
to
aid
diagnosis
PD.
The
levels
proteins
serum
collected
29
PD
patients
24
non-PD
controls
were
measured
using
enzyme-linked
immunosorbent
assays.
A
panel
four
biomarkers,
protein
disulfide-isomerase
A1,
A3,
mesencephalic
astrocyte-derived
neurotrophic
factor,
clusterin,
together
with
age
gender
had
higher
ability
(area
under
curve
0.64,
sensitivity
66%,
specificity
57%)
net
benefit
discriminate
group
compared
other
analyzed
models.
Addition
oligomeric
total
α-synuclein
model
did
not
improve
diagnostic
power
biomarker
panel.
We
provide
evidence
that
merit
further
investigation
their
potential
as
Graphical
Machine Learning and Knowledge Extraction,
Journal Year:
2024,
Volume and Issue:
6(1), P. 464 - 505
Published: Feb. 21, 2024
Alzheimer’s
disease
(AD)
is
a
pressing
global
issue,
demanding
effective
diagnostic
approaches.
This
systematic
review
surveys
the
recent
literature
(2018
onwards)
to
illuminate
current
landscape
of
AD
detection
via
deep
learning.
Focusing
on
neuroimaging,
this
study
explores
single-
and
multi-modality
investigations,
delving
into
biomarkers,
features,
preprocessing
techniques.
Various
models,
including
convolutional
neural
networks
(CNNs),
recurrent
(RNNs),
generative
are
evaluated
for
their
performance.
Challenges
such
as
limited
datasets
training
procedures
persist.
Emphasis
placed
need
differentiate
from
similar
brain
patterns,
necessitating
discriminative
feature
representations.
highlights
learning’s
potential
limitations
in
detection,
underscoring
dataset
importance.
Future
directions
involve
benchmark
platform
development
streamlined
comparisons.
In
conclusion,
while
learning
holds
promise
accurate
refining
models
methods
crucial
tackle
challenges
enhance
precision.
ACS Omega,
Journal Year:
2025,
Volume and Issue:
10(2), P. 1864 - 1892
Published: Jan. 8, 2025
Parkinson's
disease
(PD)
is
a
progressive
neurodegenerative
disorder
that
primarily
affects
movement.
It
occurs
due
to
gradual
deficit
of
dopamine-producing
brain
cells,
particularly
in
the
substantia
nigra.
The
precise
etiology
PD
not
fully
understood,
but
it
likely
involves
combination
genetic
and
environmental
factors.
therapies
available
at
present
alleviate
symptoms
do
stop
disease's
advancement.
Research
endeavors
are
currently
directed
inventing
disease-controlling
aim
inherent
mechanisms
PD.
biomarker
breakthroughs
hold
enormous
potential:
earlier
diagnosis,
better
monitoring,
targeted
treatment
based
on
individual
response
could
significantly
improve
patient
outcomes
ease
burden
this
disease.
research
an
active
evolving
field,
focusing
understanding
mechanisms,
identifying
biomarkers,
developing
new
treatments,
improving
care.
In
report,
we
explore
data
from
CAS
Content
Collection
outline
progress
We
analyze
publication
landscape
offer
perspective
into
latest
expertise
advancements.
Key
emerging
concepts
reviewed
strategies
fight
evaluated.
Pharmacological
targets,
risk
factors,
as
well
comorbid
diseases
explored,
clinical
usage
products
against
with
their
production
pipelines
trials
for
drug
repurposing
examined.
This
review
aims
comprehensive
overview
advancing
current
about
PD,
define
challenges,
assess
growth
prospects
stimulate
efforts
battling
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(3), P. 1689 - 1689
Published: Jan. 30, 2024
Neurodegenerative
diseases
are
an
increasingly
common
group
of
that
occur
late
in
life
with
a
significant
impact
on
personal,
family,
and
economic
life.
Among
these,
Alzheimer’s
disease
(AD)
Parkinson’s
(PD)
the
major
disorders
lead
to
mild
severe
cognitive
physical
impairment
dementia.
Interestingly,
those
may
show
onset
prodromal
symptoms
early
after
middle
age.
Commonly,
evaluation
these
neurodegenerative
is
based
detection
biomarkers,
where
functional
structural
magnetic
resonance
imaging
(MRI)
have
shown
central
role
revealing
or
phases,
although
it
can
be
expensive,
time-consuming,
not
always
available.
The
aforementioned
visual
system
due
pathophysiological
mechanisms
shared
between
eye
brain.
In
disease,
α-synuclein
deposition
retinal
cells,
as
well
dopaminergic
neurons
substantia
nigra,
alters
cortex
function,
resulting
modifications
field.
Similarly,
modified
by
neurofibrillary
tangles
neuritic
amyloid
β
plaques
typically
seen
brain,
this
reflect
accumulation
biomarkers
retina
during
stages
postmortem
retinas
AD
patients.
light,
ophthalmic
neurodegeneration
could
become
cost-effective
method
for
diagnosis
diseases,
overcoming
limitations
deep
This
analysis
commonly
used
practice,
interest
has
risen
recent
years.
review
will
discuss
relationship
degeneration,
highlighting
how
represent
noninvasive
straightforward
diseases.
npj Parkinson s Disease,
Journal Year:
2024,
Volume and Issue:
10(1)
Published: March 19, 2024
Abstract
Parkinson’s
disease
(PD)
is
a
highly
heterogeneous
disorder
influenced
by
several
environmental
and
genetic
factors.
Effective
disease-modifying
therapies
robust
early-stage
biomarkers
are
still
lacking,
an
improved
understanding
of
the
molecular
changes
in
PD
could
help
to
reveal
new
diagnostic
markers
pharmaceutical
targets.
Here,
we
report
results
from
cohort-wide
blood
plasma
metabolic
profiling
patients
controls
Luxembourg
Study
detect
disease-associated
alterations
at
level
systemic
cellular
process
network
alterations.
We
identified
statistically
significant
both
individual
metabolite
levels
global
pathway
activities
vs.
correlations
with
motor
impairment
scores.
As
primary
observation
when
investigating
shared
sub-network
alterations,
pronounced
coordinated
increased
abundances
xanthine
metabolism
de
novo
patients,
which
consistent
previous
case/control
transcriptomics
data
independent
cohort
terms
known
enzyme-metabolite
relationships.
From
integrated
metabolomics
analysis,
enzyme
hypoxanthine
phosphoribosyltransferase
1
(HPRT1)
determined
as
potential
key
regulator
controlling
linking
them
mechanism
that
may
contribute
pathological
loss
adenosine
triphosphate
(ATP)
PD.
Overall,
investigations
revealed
PD-associated
metabolome
including
mechanistically
congruent
observed
data.
The
HPRT1
merit
further
investigation
main
these
therapeutic
target
address
downstream
pathology
Journal of Neural Transmission,
Journal Year:
2023,
Volume and Issue:
130(6), P. 755 - 762
Published: April 17, 2023
Abstract
Blood
neurofilament
light
chain
(NfL)
is
an
easily
accessible,
highly
sensitive
and
reliable
biomarker
for
neuroaxonal
damage.
Currently,
its
role
in
Parkinson’s
disease
(PD)
remains
unclear.
Here,
we
demonstrate
that
blood
NfL
can
distinguish
idiopathic
PD
from
atypical
parkinsonian
syndromes
(APS)
with
high
sensitivity
specificity.
In
cross-sectional
studies,
some
found
significant
correlations
between
motor
cognitive
function,
whereas
others
did
not.
contrast,
prospective
studies
reported
very
consistent
associations
baseline
progression
worsening.
Amongst
subtypes,
especially
postural
instability
gait
disorder
(PIGD)
subtype,
symptoms
scores
are
reliably
linked
NfL.
Different
non-motor
comorbidities
have
also
been
associated
levels
suggesting
the
damage
of
autonomic
nervous
system
as
well
serotonergic,
cholinergic
noradrenergic
neurons
quantifiable.
Numerous
absolute
cutoff
suggested
different
cohort
studies;
however,
validation
across
cohorts
weak.
However,
age-adjusted
percentiles
intra-individual
changes
might
represent
more
valid
parameters
compared
concentrations.
summary,
has
potential
patients
to
be
used
clinical
practice
prediction
severity
progression.
Biomarkers in Neuropsychiatry,
Journal Year:
2023,
Volume and Issue:
9, P. 100074 - 100074
Published: Sept. 9, 2023
Biomarkers
in
Parkinson's
disease
are
widely
researched
the
field
of
neuropsychiatry.
Though
is
diagnosed
clinically,
biomarkers
prove
to
be
a
promising
means
identify
early
stages,
track
progression,
and
distinguish
from
other
conditions
like
dementia
with
Lewy
bodies.
There
debate
on
level
clinical
utility
specific
have.
This
state
art
review
discusses
recent
advances
search
for
delves
into
value
each,
exploring
obtained
through
different
modalities
cerebrospinal
fluid,
serum,
genetics
imaging.
Journal of Parkinson s Disease,
Journal Year:
2023,
Volume and Issue:
13(6), P. 1011 - 1033
Published: Aug. 1, 2023
Multi-arm,
multi-stage
(MAMS)
platform
trials
can
accelerate
the
identification
of
disease-modifying
treatments
for
Parkinson's
disease
(PD)
but
there
is
no
current
consensus
on
optimal
outcome
measures
(OM)
this
approach.
